[go: up one dir, main page]

MX2016004742A - Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos. - Google Patents

Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.

Info

Publication number
MX2016004742A
MX2016004742A MX2016004742A MX2016004742A MX2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A
Authority
MX
Mexico
Prior art keywords
same
preparation
piridil
ketone
derivatives
Prior art date
Application number
MX2016004742A
Other languages
English (en)
Other versions
MX377816B (es
Inventor
Tu Wangyang
Zhang Haitang
Xu Guoji
Chi Jiangtao
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MX2016004742A publication Critical patent/MX2016004742A/es
Publication of MX377816B publication Critical patent/MX377816B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de cetona pirídicos, el método de preparación de los mismos, y la aplicación farmacéutica de los mismos. Específicamente la presente invención se refiere a derivados cetona pirídicos representados por la general (I) y las sales de los mismos, método de preparación de los mismos y usos de los mismos como inhibidores de MEK y especialmente como agentes terapéuticos para cáncer, donde las definiciones de los sustituyentes en la fórmula general (I) son las mismas como la definición en la descripción. (ver Fórmula).
MX2016004742A 2013-10-25 2014-09-05 Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos. MX377816B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310512377 2013-10-25
PCT/CN2014/085976 WO2015058589A1 (zh) 2013-10-25 2014-09-05 吡啶酮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2016004742A true MX2016004742A (es) 2016-12-09
MX377816B MX377816B (es) 2025-03-11

Family

ID=52992223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004742A MX377816B (es) 2013-10-25 2014-09-05 Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.

Country Status (15)

Country Link
US (2) US9914703B2 (es)
EP (1) EP3061747B1 (es)
JP (1) JP6403172B2 (es)
KR (1) KR102222569B1 (es)
CN (1) CN104936945B (es)
AU (1) AU2014339527B2 (es)
BR (1) BR112016007396B1 (es)
CA (1) CA2927635C (es)
ES (1) ES2868450T3 (es)
MX (1) MX377816B (es)
PL (1) PL3061747T3 (es)
PT (1) PT3061747T (es)
RU (1) RU2667892C2 (es)
TW (1) TWI662026B (es)
WO (1) WO2015058589A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382056B (es) * 2015-03-27 2025-03-13 Jiangsu Hengrui Medicine Co P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación.
CN104892499B (zh) * 2015-06-26 2017-07-21 江西省科学院应用化学研究所 一种2‑吡啶酮类衍生物的合成方法
WO2018095403A1 (zh) 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
WO2018099424A1 (zh) * 2016-12-01 2018-06-07 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物的制备方法及其中间体
CN108314645A (zh) * 2017-01-18 2018-07-24 上海映诺济生物科技有限公司 一类具有抗细胞增殖活性的化合物、制备方法和用途
AU2018289864B2 (en) 2017-06-23 2022-03-31 Cstone Pharmaceuticals Coumarin-like cyclic compound as MEK inhibitor and use thereof
WO2020125747A1 (zh) * 2018-12-21 2020-06-25 基石药业（苏州）有限公司 一种mek抑制剂的晶型、无定形及其应用
CN113423398A (zh) * 2019-01-29 2021-09-21 贝达药业股份有限公司 Mek抑制剂及其在医药上的应用
CN111514140B (zh) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021018112A1 (zh) * 2019-07-29 2021-02-04 江苏恒瑞医药股份有限公司 一种1，6-二氢吡啶-3-甲酰胺衍生物的制备方法
TW202114667A (zh) * 2019-09-11 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
CN111848613B (zh) * 2020-08-11 2021-09-24 山东大学 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用
AU2022204775B2 (en) * 2021-04-14 2023-03-30 National University Corporation Hokkaido University Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN120441478A (zh) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 一种六元内酰胺类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005969A2 (en) * 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
PL2298768T3 (pl) * 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
ES2378760T3 (es) * 2005-05-18 2012-04-17 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CN101389609B (zh) * 2006-02-22 2012-01-11 霍夫曼-拉罗奇有限公司 基于乙内酰脲的激酶抑制剂
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
BRPI0910200A2 (pt) 2008-07-01 2015-09-29 Genentech Inc composto, composição farmacêutica, método de inibir o crescimento de células anormais ou de tratar um distúrbio hiperproliferativo em um mamífero e método de tratar uma doença inflamatória em um mamífero
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
US20120238599A1 (en) * 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
WO2012162293A1 (en) 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
GEP201706774B (en) * 2012-03-14 2017-11-27 Lupin Ltd Heterocyclyl compounds

Also Published As

Publication number Publication date
RU2667892C2 (ru) 2018-09-25
CN104936945A (zh) 2015-09-23
US20180016236A1 (en) 2018-01-18
PT3061747T (pt) 2021-05-04
MX377816B (es) 2025-03-11
US20160244410A1 (en) 2016-08-25
CA2927635C (en) 2021-07-20
AU2014339527A1 (en) 2016-05-12
RU2016118753A (ru) 2017-11-29
KR102222569B1 (ko) 2021-03-05
BR112016007396B1 (pt) 2021-01-19
CN104936945B (zh) 2017-11-03
EP3061747A4 (en) 2017-05-10
JP2016534027A (ja) 2016-11-04
EP3061747B1 (en) 2021-04-07
US10064848B2 (en) 2018-09-04
TWI662026B (zh) 2019-06-11
TW201518278A (zh) 2015-05-16
CA2927635A1 (en) 2015-04-30
US9914703B2 (en) 2018-03-13
EP3061747A1 (en) 2016-08-31
BR112016007396A2 (pt) 2017-08-01
ES2868450T3 (es) 2021-10-21
PL3061747T3 (pl) 2021-07-19
AU2014339527B2 (en) 2018-07-19
HK1212980A1 (zh) 2016-06-24
RU2016118753A3 (es) 2018-05-25
KR20160074554A (ko) 2016-06-28
WO2015058589A1 (zh) 2015-04-30
JP6403172B2 (ja) 2018-10-10

Similar Documents

Publication Publication Date Title
MX2016004742A (es) Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2023001876A (es) Derivados de rapamicina.
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
GT201400290A (es) Carboxamidas heterociclicas fungicidas
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
ECSP14013215A (es) Compuestos novedosos
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CO7350640A2 (es) Compuestos diméricos
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos